Company: HSDTW
Filing Date: 2025-04-15
Form Type: DRS
Source: 0001104659-25-035130
Chunk: 13

Company: Solana Co
Filing Date: 2025-04-15
Form: DRS
Chunk 13
---
 common warrants or Representative Warrants included in this offering and assuming no exercise of the option granted to the underwriters to purchase additional securities).

#### Option to purchase Additional Securities
The underwriters have a 45-day option to purchase up to additional shares of common stock and/or additional common warrants to purchase up to shares of common stock at the public offering prices less underwriting discounts and commissions. The option may be used to purchase such shares of common stock and/or common warrants, or any combination thereof, as determined by the underwriters.

#### Representative Warrants
We have agreed to issue to the representative, as defined herein, warrants to purchase up to shares of common stock (or shares of common stock assuming the exercise of the underwriters’ option in full) as a portion of the compensation payable to the representative in connection with this offering (the “Representative Warrants”). The Representative Warrants will be immediately exercisable upon issuance at an exercise price equal to $ per share of common stock, expire on the fifth anniversary

<div align='center'>6</div>

TABLE OF CONTENTS

### CONFIDENTIAL TREATMENT REQUESTED

#### PURSUANT TO 17 C.F.R. SECTION 200.83
of the commencement of sales of this offering, and are otherwise in substantially similar form to the common warrants issued in the offering. The Representative Warrants and the shares of common stock underlying the Representative Warrants are being registered on the registration statement of which this prospectus is a part. See “Underwriting” on page 22 of this prospectus.

#### Use of Proceeds
We estimate that the net proceeds from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses, will be approximately $ million (or $ million if the underwriters exercise their option to purchase additional securities in full), assuming a combined public offering price of $ per share of common stock and accompanying common warrant, which was the last reported sale price of our common stock on Nasdaq on , 2025.

We currently intend to use the net proceeds of this offering for working capital and general corporate purposes.

For additional information please refer to the section entitled “Use of Proceeds” on page 13of this prospectus.

#### Lock-up Restrictions
We and each of our directors, officers and certain stockholders are subject to certain lock-up restrictions as identified in the section titled “Underwriting.”

#### Risk Factors
Investing in our securities involves a high degree of risk and purchasers of our securities may lose their entire investment. See the information